Accuray
Builds radiation-treatment systems, planning software, and services around the CyberKnife and TomoTherapy platforms.
Something off on this page? Send us feedback.
Profile
Sells CyberKnife, TomoTherapy, and Radixact systems alongside treatment-planning, data-management, installation, training, and post-contract services. The business serves radiation-oncology providers internationally and depends on regulation, reimbursement, clinical adoption, supply chains, and product approvals.
CyberKnife, TomoTherapy, and the Radixact platform anchor a radiation-treatment portfolio for oncology providers. CyberKnife reflects the company's robotic radiosurgery heritage, while Radixact is its next-generation TomoTherapy platform used across the portfolio. Treatment-planning and data-management software, installation, training, and post-contract service extend the systems business.
Sales, distribution, strategic partnerships, and joint ventures support an international commercial model. The platforms aim to deliver advanced treatments while minimizing dose to healthy tissue.
The business depends on regulatory requirements, reimbursement, clinical adoption, international operations, supply chains, debt, foreign exchange, and product-development and approval timing.
Company facts
Key statistics
Year to date −67.6% · Average volume (30d) 1.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 12, 2026 | Jefferies | Downgrade | Buy | Hold | ||
| May 7, 2026 | BTIG | Downgrade | Buy | Neutral | ||
| Feb 5, 2026 | BTIG | Reiterate | Buy | $6 | $2 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026Q4 FY26 | −$0.03 | −$0.02 | +33.3% | $105.3M | $100.9M | −4.2% | −0.81% |
| May 6, 2026Q3 FY26 | −$0.05 | −$0.09 | −80.0% | $111.9M | $104.8M | −6.3% | −38.55% |
| Feb 4, 2026Q2 FY26 | −$0.11 | −$0.11 | −2.2% | $100.9M | $102.2M | +1.4% | −20.68% |
| Nov 5, 2025Q1 FY26 | −$0.01 | −$0.18 | −1,700.0% | $122.9M | $93.9M | −23.6% | −15.86% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $113.2M | $127.5M | $93.9M | $102.2M | $104.8M | $100.9M | |
| Gross profit | $31.6M | $39.0M | $26.5M | $24.1M | $25.3M | $35.5M | |
| Operating income | $1.0M | $4.2M | −$11.3M | −$5.5M | −$2.5M | −$7.1M | |
| Net income | −$1.3M | $1.1M | −$21.7M | −$13.8M | −$11.8M | −$1.9M | |
| Diluted EPS | −$0.01 | $0.01 | −$0.18 | −$0.11 | −$0.09 | −$0.02 | |
| Gross margin | 27.9% | 30.6% | 28.3% | 23.5% | 24.1% | 35.2% | |
| Operating margin | 0.9% | 3.3% | -12.0% | -5.4% | -2.4% | -7.0% |
Fiscal years (4-quarter sums)FY22 $429.9M · FY23 $447.6M · FY24 $446.6M · FY25 $458.5M · FY26 $401.9M
Revenue by product · Q4 FY26
Revenue by geography · Q4 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $40.6M · Total debt $183.9M · Total assets $443.7M · Shareholders' equity $41.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 118.96M · Float 113.00M · 95.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| TCW Group Inc | 18.94M | 15.92% | 13F | Aug 3, 2026 |
| Neuberger Berman Group LLC | 6.07M | 5.10% | 13G | Jul 7, 2026 |
| Armistice Capital, LLC | 5.74M | 4.82% | 13F | Aug 14, 2026 |
| Weber Capital Management LLC /Adv | 4.93M | 4.15% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.44M | 3.73% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 20, 2026 | Steven F. Mayer | director | +54,875 | $0.5627 |
| Feb 18, 2026 | Steven F. Mayer | director | +126,125 | $0.5328 |
| Feb 19, 2026 | Steven F. Mayer | director | +69,000 | $0.5304 |
| Nov 19, 2025 | Stephen R. la Neve | director, officer: CEO | +20,000 | $0.9705 |
Peers
Not reported.